Quince Therapeutics (QNCX) Set to Announce Earnings on Wednesday

Quince Therapeutics (NASDAQ:QNCX) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Quince Therapeutics to announce earnings of ($1.3850) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping the consensus estimate of ($28.02) by $15.71. On average, analysts expect Quince Therapeutics to post ($8.39) EPS for the current fiscal year and ($3.63) EPS for the next fiscal year.

Quince Therapeutics Price Performance

QNCX opened at $31.73 on Wednesday. The firm has a 50-day simple moving average of $30.68 and a two-hundred day simple moving average of $54.44. Quince Therapeutics has a 52 week low of $15.10 and a 52 week high of $909.98. The company has a market capitalization of $32.27 million, a PE ratio of -0.20 and a beta of 1.33.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on QNCX shares. Oppenheimer started coverage on Quince Therapeutics in a report on Wednesday, July 29th. They issued an “outperform” rating and a $82.00 target price on the stock. Citizens Jmp raised Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price target for the company in a research note on Tuesday, September 22nd. Raymond James Financial initiated coverage on Quince Therapeutics in a report on Friday, October 9th. They set an “outperform” rating and a $72.00 price target for the company. Zacks Research raised Quince Therapeutics to a “hold” rating in a research note on Thursday, October 1st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Quince Therapeutics in a report on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $189.88.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company is advancing therapies designed to address underlying disease mechanisms and improve outcomes for patients with serious genetic and neurological disorders.

Quince’s lead program is based on the EryDex drug-delivery platform, which uses a patient’s own red blood cells to encapsulate and gradually release a corticosteroid in the body.